Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany

PURPOSE: Treatment with CDK4/6 inhibitors and endocrine therapy (CDK4/6i + ET) is a standard for patients with advanced hormone receptor–positive, HER2-negative (HR + HER2–) breast cancer (BC). However, real-world data on the implementation of therapy usage, efficacy, and toxicity have not yet been...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast
Main Authors: Schneeweiss, Andreas, Ettl, Johannes, Lüftner, Diana, Beckmann, Matthias W., Belleville, Erik, Fasching, Peter A., Fehm, Tanja N., Geberth, Matthias, Häberle, Lothar, Hadji, Peyman, Hartkopf, Andreas D., Hielscher, Carsten, Huober, Jens, Ruckhäberle, Eugen, Janni, Wolfgang, Kolberg, Hans Christian, Kurbacher, Christian M., Klein, Evelyn, Lux, Michael P., Müller, Volkmar, Nabieva, Naiba, Overkamp, Friedrich, Tesch, Hans, Laakmann, Elena, Taran, Florin-Andrei, Seitz, Julia, Thomssen, Christoph, Untch, Michael, Wimberger, Pauline, Wuerstlein, Rachel, Volz, Bernhard, Wallwiener, Diethelm, Wallwiener, Markus, Brucker, Sara Y.
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7509062/
https://ncbi.nlm.nih.gov/pubmed/32956934
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.breast.2020.08.011
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados